Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Dayer

Showing results (151-160 of 163) with videos related to

Pageof 17
Sort By:
Clinical Pharmacology and Therapeutics|January 13, 2012
Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spotY Daali, C Samer, J Déglon, et al.
Revue Medicale Suisse|December 4, 2012
[Comparison of four drug interaction screening programs]K Ing Lorenzini, B Reutemann, C F Samer, et al.
Arthritis and Rheumatism|May 15, 2003
Neurophysiologic evidence for a central sensitization in patients with fibromyalgiaJ A Desmeules, C Cedraschi, E Rapiti, et al.
Schweizerische Medizinische Wochenschrift|January 15, 1999
[Influence of sex on reporting pain]V Piguet, J Desmeules, A F Allaz, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 1998
Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoinG C Ibeanu, J A Goldstein, U Meyer, et al.
Clinical Pharmacology and Therapeutics|April 12, 2014
Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spotsM Bosilkovska, C F Samer, J Déglon, et al.
The Pharmacogenomics Journal|July 2, 2008
The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype predictionM C Rebsamen, J Desmeules, Y Daali, et al.
British Journal of Pharmacology|July 2, 2010
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodoneC F Samer, Y Daali, M Wagner, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoinG C Ibeanu, J Blaisdell, R J Ferguson, et al.
British Journal of Pharmacology|July 2, 2010
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyC F Samer, Y Daali, M Wagner, et al.
Pageof 17

Showing results (151-160 of 163) with videos related to

Sort By:
Pageof 17
Clinical Pharmacology and Therapeutics|January 13, 2012
Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spotY Daali, C Samer, J Déglon, et al.
Revue Medicale Suisse|December 4, 2012
[Comparison of four drug interaction screening programs]K Ing Lorenzini, B Reutemann, C F Samer, et al.
Arthritis and Rheumatism|May 15, 2003
Neurophysiologic evidence for a central sensitization in patients with fibromyalgiaJ A Desmeules, C Cedraschi, E Rapiti, et al.
Schweizerische Medizinische Wochenschrift|January 15, 1999
[Influence of sex on reporting pain]V Piguet, J Desmeules, A F Allaz, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 1998
Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoinG C Ibeanu, J A Goldstein, U Meyer, et al.
Clinical Pharmacology and Therapeutics|April 12, 2014
Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spotsM Bosilkovska, C F Samer, J Déglon, et al.
The Pharmacogenomics Journal|July 2, 2008
The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype predictionM C Rebsamen, J Desmeules, Y Daali, et al.
British Journal of Pharmacology|July 2, 2010
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodoneC F Samer, Y Daali, M Wagner, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoinG C Ibeanu, J Blaisdell, R J Ferguson, et al.
British Journal of Pharmacology|July 2, 2010
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyC F Samer, Y Daali, M Wagner, et al.
Pageof 17